BenzingaAugust 13, 2026 at 2:20 AM NY2 Months Ago
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
